



exceet Group S.E.

Investor Presentation

23 November 2011

This presentation contains forward-looking statements based on beliefs of exceet Group SE management. Such statements reflect current views of exceet Group SE with respect to future events and results and are subject to risks and uncertainties. Actual results may vary materially from those projected here, due to factors including changes in general economic and business conditions, changes in currency exchange, the introduction of competing products, lack of market acceptance of new products, services or technologies and changes in business strategy.

exceet Group SE does not intend or assume any obligation to update these forward-looking statements.

■ Exceet ... at a glance	5
■ Exceet's business / positioning / end markets	6
■ Exceet's financials objectives	8
■ Exceet's financials highlights	9
■ Exceet's 9M 2011 financial review	11
■ Highlights summary	20
■ Appendix Financial statements 9M 2011	23




“We develop and produce customized products and solutions for mission critical applications.

To make our products as safe as possible we embed the security in the earliest possible stage of the individual products life cycle.”

Exceet: Who we are... at a glance

Application examples



- > Switzerland-based technology group **with strong German roots and presence, with strong skills in embedded intelligent electronics**
- > **Design, development and production of mission-critical components & solutions** to Blue Chip customers. Exceet's products are generally integrated in costly devices that are produced in relatively small and mid-sized quantities

Certifications

MedTech, Financial Services, Government

Capabilities

Quality / Reliability / Engineering & R&D Skills

Operational set-up

Flexibility
High mix / low volume
Rapid prototyping
Near-shore production


Customer proximity

Fast response times
Strong customer relationships
Joint technical developments
Mission critical products

Exceet is a trusted partner of Blue Chip players that are set to outgrow their end markets

Industry CAGR 2010-2015 by 'sub-end markets'

Underlying drivers



Source: Based on market studies prepared at the request of Helikos




Exceet's financials objectives

3 pillars: organic growth, M&A, margin expansion

1 Deliver 10-15% organic growth p.a.

- > Track record of sustained organic growth with top 10 customers
- > Organic growth opportunities driven by:
 - Organic growth of existing customers and applications
 - Organic growth of new customers and applications

Revenues (base 100):



2 Add 10-20% growth p.a. through M&A


- > Highly fragmented market
- > Increasing trend towards market consolidation
- > Already identified potential targets for 2012
- > Successful track record in terms of M&A integration

3 Lift medium term EBITDA margin to 18%

- > Profit-oriented culture
- > Room for further margin improvement

Development EBITDA margin:

Medium term target: 18%




1) Excluding one-offs IPO & Helikos/SPAC costs


Highlights (1)

- 9M revenues rose 51.5% to 128.9m€
- 20.4% organic growth
- 9M reported EBITDA grew 64.6% to 21.7m€
- 16.9% EBITDA margin
- Recurring EBITDA margin 19.1%
- 9M EBITA rose 75.8% to 17.7m€
- 13.8% EBITA margin
- 9M net profit grew 95.5% to 13.1m€
- 10.2% net margin

Group Sales (€ million)



EBITDA (€ million)




H1 2011& 9M 2011 EBITDA margin excl. one-off IPO and Helikos/SPAC costs (-2.9m€).

- 9M Free cash flow* reached 8.4m€, up 114% vs 9M10
- Solid Balance sheet, showing net debt of 1.1m€, down from 17.6m€ at the end of Dec 10
- Order book reached 104m€
- 2011 prospects: exceet continues to see strong demand across its medtech and security solutions. Detailed guidance for FY12 will be disclosed when exceet reports FY11 preliminary sales (expected in February 2012)

*Free Cash Flow = Cash Flow From Operations (as per Cash Flow Statement) less Net Capex (excluding the deduction of finance leases)


Financial review and analysis

Revenue bridge from actual 9M 2010 to actual 9M 2011




- Organic revenue growth reached 18.8 m€, reflecting +20.4% organic growth rate
- 9M10 'Like for like' revenues integrate Winter's contribution as if Winter had been consolidated from January 1, 2010 (as a reminder, Winter was consolidated from December 29, 2010)
- FX adjustments mainly reflect the impact of strengthening CHF vs. the € (+14% during the period)
- 2011 scope changes reflect the impact of AthentiDate and Contec, respectively consolidated on April 1, 2011 and May 1, 2011

Revenue bridge from actual Q3 2010 to actual Q3 2011




- Organic revenue growth reached 6.9m€, reflecting +19.7% organic growth rate
- Q310 'Like for like' revenues integrate Winter's contribution in full Q310, as if Winter had been consolidated from January 1, 2010
- FX adjustments mainly reflect the impact of strengthening CHF vs. the € (up 14% year on year)
- 2011 scope changes reflect the impact of AthentiDate and Contec, respectively consolidated on April 1, 2011 and May 1, 2011

EBITDA bridge from actual 9M 2010 to actual 9M 2011




- 9M reported EBITDA grew 64.6% to 21.7m€, reflecting 16.9% EBITDA margin, despite negative impact of one-off IPO and Helikos/SPAC costs (-2.9m€)
- Excluding one-offs, recurring EBITDA margin would have reached 19.1%

EBITDA bridge from actual Q3 2010 to actual Q3 2011



- In Q3 exceet reported 18.7% EBITDA margin (**excluding one-offs, recurring EBITDA margin would have reached 19.6%**)
- Notably, exceet delivered strong EBITDA margin despite the dilutive impact of Contec and AuthentiDate


From EBITDA to Free Cash Flow for 9M 2011



- **9M Free cash flow reached 8.4m€, up 114% vs. 9M10:** under the combined impact of rising EBITDA and fairly stable Capex, which have more than offset the WCR growth experienced in Q3
- **WCR usually picks in Q3 and reverses in Q4,** as exceet generally sells its high Q3 inventories in Q4. Moreover, receivables tend to decline in Q4, given the weak activity in the 2nd half of December (also seasonal)
- Capital expenditures were focused mainly on production and equipment as well as the purchase of land in connection with the acquisition of Contec GmbH in Tirol. Capital expenditures representing 2.5% of revenues were invested in property, plant and equipment in the first nine months of 2011



Net Debt evolution between 12/31/10 and 09/30/11



Net debt declined from 17.6m€ at the end of December 2010 to 1.1m€ at the end of September 2011.


By order of importance:

- The Helikos transaction translated into 20.6m€ inflow (itself mainly driven by 15.1m€ capital increase in the framework of the IPO)
- Free Cash Flow generation in the first 9 months of 2011 (8.4m€)
- The 2-above mentioned cash inflows were partially mitigated by acquisition spending (Contec & AuthentiDate for 6.4m€)


*mainly covers the redemption of a shareholder loan, included in the 20.6m€ effects of the Helikos transaction

9M 2011: Reported 9M 2011 vs. medium-term targets


Group Sales (€ million)




Organic Sales Growth Rate (%)



Recurring EBITDA (€ million)



Recurring EBITDA Margin (%)



*2010 : excluding Winter



'Below EBITDA' items

- Depreciation & Amortization charges reached 5.9m€, up 40.5% vs 9M10, due to increase asset base as a result of both organic growth and acquisitions. **Despite D&A increase, EBIT (+75.9%) grew faster than EBITDA (+64.6%)**
- Notably, Amortization of PPA* charge reached 1.9m€ in 9M11, up from 1.1m€ in 9M10, purely driven by the full year impact of Winter's acquisition, as well as additional amortization incurred in 2011 in relation with the Contec and AuthentiDate acquisitions. **EBITA margin expansion (up 190 bps to 13.8%) was higher than EBIT margin expansion (up 170 bps to 12.3%)** because the growth of PPA amortization was higher than the increase in depreciation charges
- Net financial income of +1.6m€, vs net financial expense of -1.05m in 9M10, mainly driven by +2m€ income associated with mark-to-market valuation of the warrants
- Reported tax rate of 24.5% in line with exceet's normalized tax rate 25-26%
- **2011 prospects:** exceet continues to see strong demand across its medtech and security solutions. Detailed guidance for FY12 will be disclosed when exceet reports FY11 preliminary sales results (expected in February 2012)




*Purchase Price Allocation (Amortization related to Customer Base, Technology and Brand acquired in relation with M&A transactions)

Strong Financials

- > Sales revenue up 51.5% to 128.9 m€ in 9M11 (+20.4% organic growth)
- > EBITDA up 64.6% to 21.7m€: EBITDA margin improved to 16.9% in 9M11 (19.1% ex one-offs)
- > Free cash flow of +8.4m€ (up 114% vs. 9M10)
- > Net debt reduced to 1.1m€ at the end of September 2011
- > Cash & cash equivalents of 37.4m€
- > Outlook 2011: consistent with the strong performance achieved in 9M11

Strong Fundamentals

- > Robust business model and proven track record of both organic and external growth
- > Strong underlying end-markets and actionable growth and earnings opportunity
- > High-quality portfolio of blue chip customers
- > Experienced and aligned management team
- > Defined acquisition roadmap



Thank you
for your attention

Appendix

Group income statement

9 Month 2011 vs. 9 Month 2010

	(in €m)	9m 2011	9m 2010
Revenue		128,9	85,1
Cost of sales		-95,1	-66,3
Gross profit		33,8	18,7
% margin		26,2%	22,0%
Distribution costs		-7,4	-5,7
Administrative expenses		-11,7	-5,0
Other operating income		1,0	1,0
EBIT		15,8	9,0
% margin		12,3%	10,6%
Net financial result		1,6	-1,1
Profit before tax		17,4	7,9
Income tax		-4,3	-1,2
Net profit		13,1	6,7
% margin		10,2%	7,9%

Key Financial Indicators			
Reported EBIT		15,8	9,0
+ PPA Amortization		1,9	1,1
= EBITA		17,7	10,1
EBITA margin		13,8%	11,9%
Reported EBIT		15,8	9,0
+ Depreciation charges & Amortization		5,9	4,2
+ Non recurring items		2,9	0,0
= Recurring EBITDA		24,6	13,2
% Recurring EBITDA margin		19,1%	15,5%

Sales and profit per segment

9 Month 2011 vs. 9 Month 2010

	ECMS		IDMS		ESS		Corporate an others		Intersegment elimination		Group consolidation	
[in €m)	1.1.2011 to 30.09.2011	1.1.2010 to 30.09.2010	1.1.2011 to 30.09.2011	1.1.2010 to 30.09.2010	1.1.2010 to 30.09.2010	1.1.2011 to 30.09.2011	1.1.2011 to 30.09.2011	1.1.2010 to 30.09.2010	1.1.2010 to 30.09.2010	1.1.2011 to 30.09.2011	1.1.2011 to 30.09.2011	1.1.2010 to 30.09.2010
External revenue	93.2	59.2	32.6	26.0	3.1	0	0	0	0	0	128.9	85.1
Intersegment revenue	0	0	0.6	0	0	0	0.3	0.2	-0.9	-0.2	0	0
Total revenue	93.2	59.2	33.2	25.9	3.1	0	0.3	0.3	-0.9	-0.2	128.9	85.1
Operating result (EBITDA)	24.2	13.1	3.0	2.0	0.4	0	-5.9	-2.0	0	0	21.7	13.2

Cash flow statement

9 Month 2011 vs. 9 Month 2010

	9m 2011	9m 2010
Profit before income tax	17,4	7,9
Depreciation & amortization	5,9	4,2
Other non cash items	-0,7	0,4
Interest Income/(expense), net	-1,1	1,0
Operating results before changes in net working capital	21,5	13,5
Changes to net working capital	-7,9	-4,4
Tax paid (net)	-1,2	-1,4
Interest paid (net)	-0,7	-0,3
Cashflows from operating activities	11,6	7,4
Reverse asset acquisition, net of cash acquired	131,1	0,0
Acquisition of subsidiaries, net of cash acquired	-6,3	0,0
Net Capex	-3,0	-1,8
Cashflows from investing activities	121,7	-1,8
Acquisition of non-controlling interests	-0,1	0,0
Repayments/proceeds of borrowings & repayment of finance lease	-3,7	-4,3
Distribution of profit to shareholder	-110,5	0,0
Cashflows from financing activities	-114,2	-4,3
Net changes in cash and cash equivalents	19,1	1,3
Cash and cash equivalents at the beginning of the period	18,9	10,9
Effect of exchange rate gains/(losses)	-0,6	0,7
Cash and cash equivalents at the end of the period	37,4	12,9


Balance sheet

9 Month 2011 vs. December 31, 2010

ASSETS		
	unaudited Sept 30, 2011	Dec 31, 2010
Tangible assets	26,0	21,0
Intangible assets	52,3	47,2
Other non current asset	0,3	0,3
Inventories	34,4	22,3
Trade receivables, net	23,6	16,3
Other current receivables	2,6	1,0
Current income tax receivable	1,2	0,8
Cash and cash equivalents	37,4	18,9
Total assets	177,6	127,8
LIABILITIES		
Total equity	85,2	56,0
Borrowings	33,3	18,8
Retirement benefit obligations	5,6	4,1
Deferred tax liabilities	7,6	6,5
Non current Provisions & others	2,4	0,9
Trade payables	9,5	9,1
Other current liabilities	23,0	13,5
Current Borrowings	5,2	17,8
Current Provisions & others	5,7	1,1
Total liabilities	92,4	71,8
Total equity and liabilities	177,6	127,8

History of Exceet

Exceet's history



Foundation dates



1) Including NovaCard GmbH, idVation GmbH, PPC Card Systems GmbH/B.V., VisionCard GmbH. 2) Closing occurred in April/May 2011. 3) Infineon spin-off.

Source: Exceet

Production site overview

Production sites



Comments

Company	Location	Key products
CONTEC ⁽²⁾	Ebbs, Austria	> Electronic systems and components
PPC CardSystems	Paderborn, Germany Groningen, Netherlands	> Smartcards and card personalisation
AEMtec	Berlin, Germany	> Electronic systems and electronic modules, Miniaturisation
ECR ELECTRONICS	Rotkreuz, Switzerland	> Electronic systems and electronic modules, express manufacturing capabilities
GS SWISS PCB	Küssnacht, Switzerland	> PCBs, express manufacturing capabilities
mikrap	Einsiedeln, Switzerland	> Production of electronic systems, electronic modules, embedded software
the Art of packaging	Zernovice, Czech Republic	> Prelaminates for RFID card components, packaging services
VisionCard	Kematen, Austria	> Smartcards
WINTER Card Services	Unterschleissheim, Germany	> Smartcards, card personalisation > Secure data management

1) 2010 average utilisation based on regular 5-day week (one shift). 2) Acquisition of Contec closed in May 2011

Operational business set-up

**Delivery of tailor-made mission critical solutions and high margin
small/medium volume series production**

Operational footprint



Close-to-customer' model

- > Production facilities with advantageous customer proximity
- > Fast response times through customer proximity
- > Strong customer relationships leading to joint technical developments

Manufacturing excellence

- > Modern production equipment
- > Flexible manufacturing organisation allows business to capture profitable small to mid-size series production
- > Seamless from rapid prototyping to serial production
- > Near-shore production facility

Operational synergy fields

- > Procurement
- > Production / rapid prototyping
- > Operations
- > Sales / distribution

Proven and experienced management team



CEO **Ulrich Reutner**

Strategy and Corporate Development

2008 Founder VisionCard
2004/2008 ACG Group/ITG Group
2002/2003 AEG Identifikationssysteme, MD
2001/2002 Multitape GmbH, MD
Studied Engineering at University of Mannheim, Germany



CFO **Ulrich Feisst**

Finance, M&A, Legal, IR

2007/2009 AEM technologies; Board Member
2006/2007 AEM technologies, Business Development
2001/2006 Berlin Capital Fund, Investment Director
1994/2001 EUTELIS Consult, Managing Consultant
Studies Economics at University of Hohenheim, Germany



COO **Robert Wolny**

Operations

2002/2006 Assa Abloy Holding, MD
2002/2006 Vision Card, MD
2001/2002 Schwab Packaging, MD
2000/2002 Schwab Partner, MD
1987/2000 Schwab Druck, Kartonagen, various Management positions



CIO **Jan Trommershausen**

M&A, Acquisition Integration, HR

2009/2010 Novacard, MD
2006/2009 Card Factory, Board Member
2004/2005 Westag & Getalit, Board Member
2001/2004 SaarGummi, Managing Spokesman
1998/2001 DBT, Maschinenfabrik Scharf, MD
Studied Business Administration at University of Münster, Germany



Dan Negrea

Chief Technology Officer

2008 CTO AEMtec, Managing Director
2002/2008 Vatron Tech., R&D Head Switzerland
1995/2002 GN Resound, R&D Manager
1993/1995 Bruel & Kjaer, Tech. Account Manager
1990/1993 Olivetti, Technical Service
Completed MBA from IMADEC University Austria



Fabian Rau

Head of Investor Relations

2002/2010 Cenit AG, Marketing & IR
1997/2000 Cubis AG, Director IR
1995/1997 IBM, Communications Manager
1993/1995 Kunst+Ausstellungshalle, Press Assistant



Dr. Frank Bosa

CEO, GS Swiss PCB

Since 2002 GS Swiss PCB, CEO
2006/2007 Freelance Consultant
2001/2006 Applied Material, Process Engineer
1994/2001 Bruker-Spectrospin, Electronics Engineer
Doctor of Technical Sciences from ETH Zurich, Switzerland



Jan Wendenburg

Head of ESS, CEO AuthentiDate

Since 2002 Founder of AuthentiDate & CEO
1998/2000 Windhorst Group, MD
1985/1998 IBM Germany, Sales
1981-1985 Kaufhof AG, Manager
Completed MBA from Open University Business School, Belgium

... supported by a knowledgeable board

Exceet's Board



Hans Hofstetter

Partner at law firm
Schoch, Auer & Partner



Thomas Brauchli

Partner at law firm
Schoch, Auer & Partner



Ulrich Reutner

CEO, Exceet



Roland Lienau

MD Wendel



**Dirk-Jan
Van Ommeren**

CEO Oranje-Nassau, a
Wendel business




Dr. Hagen Hultzs

Holder of various
board positions

Shareholders structure

Outstanding Number of public shares Class A relevant for Market Cap: 20,523,695



Company's voting share capital currently amount to 34.734.221 shares, consisting in 25.175.00 class A shares (public shares), thereof 5.101.305 treasury shares (« redeemed shares ») held by exceet. A total of 4.651.305 shares will be canceled, according to the company by-laws

Class A-Shares outstanding:

- Total number of class A shares outstanding: 25,175,000
 - thereof 5,101,305 treasury shares (“redeemed shares”) held by exceet. A total of 4,651,305 shares will be canceled, according to the company by-laws
- ➔ **Remaining total number of class A shares 20,523,695**

Class B-Shares outstanding:

- 5.210,526 million class B shares (“founder shares”) are currently outstanding and held by the founders of Helikos S.E. They will convert into class A shares on achievement of share price targets:
 - 1.0 m shares at €12 (granted in exchange for giving up 10.0 m warrants)
 - 2.1 m shares at €14
 - 2.1 m shares at €16
- ➔ **Maximum number of class A shares into which class B shares can convert 5,210,526**

Class C-Shares outstanding:

- 9.0 million class C shares (“earn-out shares”) were issued to the vendors and will convert into class A shares on achievement of share price targets:
 - 3.0 m shares at €12
 - 3.0 m shares at €13
 - 3.0 m shares at €15
- ➔ **Maximum number of class A shares into which class C shares can convert 9,000,000**
- ➔ **Maximum number of class A shares after dilution 34,734,221 (at share-price of €16)**
- ➔ **(Including 450.000 reserved for MSOP)**

Public Warrants:

- 20.0 m public warrants outstanding:
 - Strike price €12 and capped at €17
 - Exercise period 5 years from close of business combination July 26th 2011
 - We assume that at share price triggers of € 13.0, € 14.0, €15.0, € 16.0, € 17.0 each, 20% of the warrants will “cashless” convert into class A shares
- ➔ **Maximum number of class A-Shares from converted warrants 1.927.796**
- ➔ **Fully diluted shares outstanding at a share price of 17 €: 36,662,017**
- ➔ **Transaction & Use of Cash**
- –€110.5m cash considerations to sellers
 - –€15,1m for capital increase at exceet
 - –€12.5m in payments to public warrant holders

1) number of Warrant Shares =
$$\frac{\text{number of Class A warrants exercised} \times (\text{Fair Market Value} - \text{Exercise Price})}{2 \times \text{Fair Market Value}}$$

Contac:

Fabian Rau
Vice President
Marketing/Investor Relations
exceet Group SE
114, avenue Gaston Diderich
L-1420 Luxembourg
www.exceet.ch

Mobile:	+41 79 312 59 98
Phone:	+41 41 499 93 25
Email:	f.rau@exceet.ch

